$43.23 -0.53 (%) Seattle Genetics Inc - NASDAQ

May. 22, 2015 | 04:00 PM

Partner Headlines

  1. Insiders keep on buying Macerich Co and Seattle Genetics

    GuruFocus | May. 22, 2015 | 17:46PM EST
  2. Earnings Scheduled For February 10, 2015

    Benzinga | Feb. 10, 2015 | 04:42AM EST
  3. From Coca-Cola To Tesla, Here Are The 68 Most Important Earnings Expectations For The Week

    Benzinga | Feb. 8, 2015 | 10:43AM EST
  4. 10 Biotech Stories You Might've Missed This Week

    Benzinga | Jan. 15, 2015 | 13:18PM EST
  5. Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 1

    Benzinga | Jan. 12, 2015 | 08:55AM EST
  6. New Biotech ETF From ALPS

    Benzinga | Jan. 2, 2015 | 08:05AM EST
  7. 5 Health Care Stocks Hurting From The Affordable Care Act

    Benzinga | Nov. 4, 2014 | 20:46PM EST
  8. Seattle Genetics: Can Record Growth From Its Licenses

    GuruFocus | Oct. 28, 2014 | 15:50PM EST
  9. Bank Of America Q3 Small & Mid-Cap Biotech Preview

    Benzinga | Oct. 20, 2014 | 16:58PM EST
  10. Benzinga's Top Downgrades

    Benzinga | Sep. 30, 2014 | 09:00AM EST
  11. Bank of America Downgrades Seattle Genetics To Underperform

    Benzinga | Sep. 30, 2014 | 08:38AM EST
  12. Seattle Genetics Offers Updated Progression-Free Survival, Overall Survival Data from ADCETRIS Frontline PTCL Phase 1 Trial

    Benzinga | Sep. 24, 2014 | 09:01AM EST
  13. Seattle Genetics: Can Record Sustained Growth From Royalty

    GuruFocus | Aug. 31, 2014 | 14:33PM EST
  14. Will ImmunoGen's Q4 Earnings Disappoint Again?

    GuruFocus | Jul. 30, 2014 | 19:21PM EST
  15. UPDATE: UBS Upgrades Seattle Genetics

    Benzinga | Jul. 9, 2014 | 11:44AM EST
  16. Target And Others Insiders Have Been Buying

    Benzinga | Jun. 8, 2014 | 14:30PM EST
  17. UPDATE: Bank Of America Upgrades Seattle Genetics

    Benzinga | May. 6, 2014 | 09:31AM EST
  18. UPDATE: Bank of America Upgrades Seattle Genetics On Trial Risks

    Benzinga | May. 6, 2014 | 09:06AM EST
  19. Benzinga's Top Upgrades

    Benzinga | May. 6, 2014 | 07:57AM EST
  20. US Stock Futures Flat Ahead Of International Trade Data

    Benzinga | May. 6, 2014 | 07:29AM EST
  21. Seattle Genetics Achieves Milestones Under Collaboration with Takeda for Achieving First Commercial Sales of ADCETRIS

    Benzinga | Apr. 8, 2014 | 09:02AM EST
  22. UPDATE: H.C. Wainwright & Co. Initiates Coverage on Seattle Genetics on Good Potential for Adcetris

    Benzinga | Mar. 10, 2014 | 09:20AM EST
  23. UPDATE: Bank of America Reinstates Coverage on Seattle Genetics as High Expectations are Priced In

    Benzinga | Feb. 24, 2014 | 08:37AM EST
  24. 2 Deaths, 25% Plunge -- And Still A Big Upside

    YCharts | Feb. 12, 2014 | 09:31AM EST
  25. Office Depot, Seattle Genetics And Others Insiders Have Been Buying

    Benzinga | Dec. 21, 2013 | 17:02PM EST
  26. Seattle, Genetics Takeda Highlight Long-term Follow-up Data from ADCETRIS Pivotal Clinical Trials at ASH

    Benzinga | Dec. 9, 2013 | 11:27AM EST
  27. Seattle Genetics Presents Interim Phase 1 from Novel Antibody-Drug Conjugate SGN-CD19A at ASH 2013

    Benzinga | Dec. 7, 2013 | 11:03AM EST
  28. Gilead Sciences Leads In Rising Short Interest Among Biotechs

    Benzinga | Nov. 12, 2013 | 16:41PM EST
  29. Short Sellers Retreat From Biogen Idec, Move On Pharmacyclics (BIIB, BMRN, PCYC)

    Benzinga | Oct. 25, 2013 | 15:36PM EST
  30. Seattle Genetics Initiates Phase 1 LIV-1-Positive Metastatic Breast Cancer Trial of SGN-LIV1A

    Benzinga | Oct. 21, 2013 | 09:17AM EST
  31. Short Sellers Move On Amgen, Vertex (AMGN, PCYC, VRTX)

    Benzinga | Oct. 11, 2013 | 14:33PM EST
  32. BioMarin, Celgene Lead Trend in Biotech Short Interest (BRMN, CELG, REGN)

    Benzinga | Sep. 25, 2013 | 12:52PM EST
  33. Alexion, Pharmacyclics Buck Trend in Biotech Short Interest (ALXN, CELG, PCYC)

    Benzinga | Sep. 14, 2013 | 11:47AM EST
  34. Seattle Genetics Commences Two Phase I Trials of SGN-CD19A

    Benzinga | Feb. 6, 2013 | 02:03AM EST
  35. Seattle Genetics, Inc. (SGEN) President and CEO Clay B Siegall sells 2,000 Shares

    GuruFocus | Feb. 5, 2013 | 14:07PM EST
  36. Seattle Genetics and Millennium Initiate Global Phase III Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in Front-line CD30-Expressing Mature T-Cell Lymphoma (MTCL)

    Benzinga | Jan. 24, 2013 | 02:02AM EST
  37. Seattle Genetics, Inc. (SGEN) President and CEO Clay B Siegall sells 8,249 Shares

    GuruFocus | Jan. 4, 2013 | 13:08PM EST
  38. Seattle Genetics, Inc. (SGEN) COO Eric Dobmeier sells 50,983 Shares

    GuruFocus | Jan. 4, 2013 | 13:07PM EST
  39. Seattle Genetics Inc. (SGEN) COO Eric Dobmeier sells 50,000 Shares

    GuruFocus | Dec. 19, 2012 | 11:51AM EST
  40. Seattle Genetics Inc. (SGEN) COO Eric Dobmeier sells 50,000 Shares

    GuruFocus | Dec. 19, 2012 | 11:51AM EST
  41. Seattle Genetics, Inc. (SGEN) COO Eric Dobmeier sells 50,000 Shares

    GuruFocus | Dec. 19, 2012 | 11:06AM EST
  42. Seattle Genetics Offers Data on Next-Gen Antibody-Drug Conjugate SGN-CD33A at ASH Annual Meeting

    Benzinga | Dec. 10, 2012 | 03:03AM EST
  43. Seattle Genetics Presents Encouraging ADCETRIS Data in CD30-Positive Non-Hodgkin Lymphomas and Other Malignancies

    Benzinga | Dec. 9, 2012 | 04:07AM EST
  44. Seattle Genetics, Inc. (SGEN) President and CEO Clay B Siegall sells 8,250 Shares

    GuruFocus | Dec. 4, 2012 | 14:06PM EST
  45. Seattle Genetics, Inc. (SGEN) COO Eric Dobmeier sells 27,327 Shares

    GuruFocus | Nov. 15, 2012 | 13:35PM EST
  46. Seattle Genetics Falls After Q3 Results and Analyst Downgrade

    Benzinga | Nov. 8, 2012 | 07:26AM EST
  47. Seattle Genetics, Inc. (SGEN) President and CEO Clay B Siegall sells 8,250 Shares

    GuruFocus | Nov. 2, 2012 | 13:36PM EST
  48. Millennium, Seattle Genetics Announce Phase 3 Clinical Trial of ADCETRIS

    Benzinga | Nov. 1, 2012 | 02:17AM EST
  49. Seattle Genetics Announces EC Conditional Marketing Authorization ADCETRIS

    Benzinga | Oct. 31, 2012 | 01:06AM EST
  50. Seattle Genetics Will Get Undisclosed Milestone Payments

    Benzinga | Oct. 9, 2012 | 03:01AM EST
Trading Center